Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Nonalcoholic Steatohepatitis (NASH) Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

3 recruiting trials for Nonalcoholic Steatohepatitis (NASH). Eligibility criteria explained in plain English.

TrialFinderData lists 3 Nonalcoholic Steatohepatitis (NASH) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 1 is the largest group at 50% (1 studies); the largest phase groups are Phase 1: 1, Phase 2: 1.

Research is led by Changchun Intellicrown Pharmaceutical Co. LTD (1), Centre hospitalier de l'Université de Montréal (CHUM) (1), Polaris Group (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Placebo (drug, 2 trials), followed by IMM-H014, IMM-H014 ( FE).

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
3
Total Trials
3
Recruiting Now
0
Phase 3 Trials
3
Sponsors

Track Nonalcoholic Steatohepatitis (NASH) trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 1NCT06216041

To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects

This study will evaluate the safety, tolerability and pharmacokinetics (PK) of escalating single- and multiple-oral doses of IMM-H014 on fasted condition, and characterize PK of...

Sponsor: Changchun Intellicrown Pharmaceutical Co. LTDEnrolling: 1381 location
RECRUITINGNCT03572465

Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis

Nonalcoholic fatty liver disease is the most common liver disease in Western countries, due in large part to its association with type 2 diabetes and obesity. The more advanced...

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)Enrolling: 1021 location
RECRUITINGPhase 2NCT05842512

Study of ADI-PEG 20 Versus Placebo in Subjects With NASH

Evaluate efficacy and safety of ADI-PEG 20 in patients with NASH

Sponsor: Polaris GroupEnrolling: 6010 locations

Frequently Asked Questions

There are currently 3 clinical trials for Nonalcoholic Steatohepatitis (NASH), with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Nonalcoholic Steatohepatitis (NASH), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Nonalcoholic Steatohepatitis (NASH), representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.